May 21, 2026
Adults with ADHD and a coexisting substance use disorder (SUD) are nearly twice as likely to discontinue treatment with medication compared to their peers with ADHD only, according to a new study published in BMJ Mental Health.1
The Swedish cohort study found that almost half (44%) of adults with ADHD and substance use disorder stopped medication within one year of diagnosis or first SUD-related event, compared to 25% in the ADHD-only group. (The study defined medication discontinuation as a treatment gap of 90 days or more without medication, calculated based on the estimated duration of the previous prescription.) Individuals with a history of abuse of stimulants, cannabis, and/or multiple SUDs experienced significantly higher risks for treatment discontinuation.
Though many patients eventually resumed treatment, those with ADHD and SUD did so at a much lower rate. Notably, individuals with substance-related criminal justice involvement were the least likely to reinitiate ADHD treatment.
“ADHD is often overlooked in prison populations and seldom treated appropriately,” the researchers wrote.2 “Whether this is due to patients experiencing difficulties engaging and adhering to treatment regimens or whether healthcare providers are reluctant to prescribe stimulants to patients with ADHD and SUD in the presence of criminal history, or consider treating this patient group riskier and therefore more often discontinue treatment, is unclear. It is, however, increasingly clear that healthcare services need to be adapted to the specific needs of patients with ADHD, SUD, and criminality to reach more patients and improve long-term outcomes.”3
Though guidelines recommend stimulants as the first-line treatment for ADHD in adults, some clinicians remain wary of using stimulant medication to treat patients with coexisting SUD. Concerns often center on the abuse potential of stimulants; however, ADHD treatment with stimulant medication does not cause future drug misuse or addiction, explained Timothy E. Wilens, M.D., during the ADDitude webinar, “Substance Use Disorder and ADHD: Safe, Effective Treatment Options.”
“In fact, the opposite appears to be true,” Wilens said. “Studies show that early treatment of ADHD and its continued treatment across the lifespan reduce risk for substance use and SUDs.”4
Some clinicians prescribe lower doses of ADHD medication for SUD populations out of caution. However, findings showed lower doses did not improve adherence; higher doses did.
This finding suggests that patients who tolerate stimulants well are more likely to continue treatment, which could prevent criminal behaviors. Patients with ADHD, early onset SUD, and coexisting conduct disorder are at a higher risk for criminality, but those who adhere to their ADHD treatment are better able to avoid it, according to a 2012 population-based Swedish study involving 26,000 adults with ADHD who had criminal convictions. The study, published in the New England Journal of Medicine, found that the crime rate decreased by 32% for men who had taken their ADHD medication. The drop in crime was even bigger for women: 41%.5
A 2025 BMJ study found that ADHD medication use is significantly associated with lower rates of first-time and recurring suicidality, criminal behaviors, vehicular accidents, and substance misuse.6
“This may be because people with multiple occurrences of such events typically have more severe ADHD, making them more likely to benefit from drug treatment,” the study’s authors wrote. “Additionally, the cumulative effect of ADHD drug treatment may lead to additive improvements over time, whereas negative consequences may accumulate the longer an individual goes untreated.”
Factors Influencing Treatment Discontinuation and Reinitiation
The researchers on the BMJ Mental Health study stressed the need to improve medication continuity for individuals with ADHD and SUD. They recommended that treatment providers consider the specific needs of individuals with ADHD and SUD to improve outcomes, especially in young males, who were more likely to discontinue treatment compared to females.
Study results showed those with ADHD and SUD were more likely than those with ADHD only to change providers and medication type between discontinuation and reinitiation of treatment.
“SUD patients, especially those with more severe SUD, have difficulties accessing and engaging with the healthcare system, due to stigma and low health literacy,” the researchers wrote. “Such factors, although impossible to explore using register data, may contribute to the increased risk of treatment discontinuation and lower reinitiation.”
Age also influenced treatment discontinuation and reinitiation. In the ADHD and SUD group, young adults between the ages of 18 and 24 years or younger at the time of their first SUD event were more likely to stop and less likely to restart treatment compared to those with only ADHD.
“Given that treatment adherence has been associated with positive outcomes in both ADHD and SUD, it is important to improve treatment access and continuity of care, especially in the susceptible period during the transition between adolescence and adulthood, a period marked by heightened vulnerability for both SUD onset and for treatment discontinuation,” the researchers wrote.
The study included a total of 55,684 people between the ages of 16 and 26 from Swedish national registers (9,283 people with ADHD and SUD and 46,401 with ADHD only), who had ongoing ADHD medication treatment.
According to Wilens, about one in two adolescents and one in four adults with an SUD has co-occurring ADHD; the risk for SUD is even higher among adolescents and adults with untreated ADHD.7, 8
“Given the known links between ADHD and SUD, adolescents and adults with SUDs or problematic substance use should be screened for ADHD,” he said. “For individuals with both SUDs and ADHD, structured therapies such as cognitive behavioral therapy (CBT) and pharmacological approaches appear most effective. Treatment may start, for example, with CBT that focuses initially on SUD than on the ADHD. Throughout treatment, providers may alternate between focusing on the SUD and ADHD, helping patients understand and identify their thoughts and feelings around substance cravings and urges, and managing symptoms and other ADHD-related issues that may interfere with substance use treatment. Patients also learn how to keep themselves out of high-risk situations.”
Sources
1Capusan AJ, Zhang L, Larsson H, et al. (2026). Discontinuation and reinitiation of pharmacological treatment for ADHD among individuals with ADHD and substance use disorder. BMJ Ment Health. https://mentalhealth.bmj.com/content/29/1/e302138
2Retz, W., Ginsberg, Y., Turner, D., et al. (2021). Attention-deficit/hyperactivity disorder (ADHD), antisociality, and delinquent behavior over the lifespan. Neurosci Biobehav Rev. https://doi.org/10.1016/j.neubiorev.2020.11.025
3Mariani, J.J., Levin, F.R. (2007). Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict. https://doi.org/10.1080/10550490601082783
4Boland, H., DiSalvo, M., Fried, R., Woodworth, K.Y., Wilens, T., Faraone, S.V., & Biederman, J. (2020). A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. Journal of psychiatric research. https://doi.org/10.1016/j.jpsychires.2020.01.006
5Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012). Medication for attention deficit-hyperactivity disorder and criminality. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1203241
6Zhang. L., Zhu, N., Sjölander, A., Nourredine, M., Li, L., Garcia-Argibay, M. et al. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ. https://doi.org/10.1136/bmj-2024-083658
7van Emmerik-van Oortmerssen, K., van de Glind, G., van den Brink, W., Smit, F., Crunelle, C. L., Swets, M., & Schoevers, R. A. (2012). Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug and alcohol dependence. https://doi.org/10.1016/j.drugalcdep.2011.12.007
8Wilens, T.E., & Morrison, N.R. (2012). Substance-use disorders in adolescents and adults with ADHD: focus on treatment. Neuropsychiatry. https://doi.org/10.2217/npy.12.39